NC-BIOVENTUS
Bioventus , a global leader in orthobiologic solutions, has entered into a development collaboration agreement with MTF Biologics , the world’s largest tissue bank, to co-develop a next generation placental tissue product for the treatment of painful musculoskeletal conditions, with an initial focus on knee osteoarthritis (OA). Terms of the agreement were not disclosed.
“Development of new orthobiologics offerings for osteoarthritis is a core focus for Bioventus and we are pleased to begin collaborating with MTF Biologics on a solution for knee OA that will offer symptom relief and potentially delay progression of the disease,” said Tony Bihl, CEO, Bioventus. “We also expect to work together to develop additional uses and indications for this product as part of this program. There is a promising and growing body of preclinical and clinical evidence underscoring the potential of these preparations in supporting the body’s natural healing processes thanks to the inherent growth factors and regulatory molecules present in placental tissues.”
“MTF Biologics is excited to begin working with Bioventus to bring this new solution to market,” said Joe Yaccarino, President and CEO, MTF Biologics. “Through this relationship we expect to co-develop and deliver innovative biologic products for orthopaedics to patients and physicians.”
About MTF Biologics
MTF Biologics, also known as the Musculoskeletal Transplant Foundation, is a nonprofit organization based in Edison, N.J. It is a consortium comprised of leading organ procurement organizations, tissue recovery organizations and academic medical institutions, and governed by a board of surgeons who are leading experts in tissue transplantation. As the world’s largest tissue bank, MTF Biologics saves and heals lives by honoring donated gifts, serving patients and advancing science. Since its inception in 1987, the organization has received tissue from more than 132,000 donors and distributed more than 8.6 million grafts for transplantation. Through its IIAM subsidiary, it has placed more than 58,000 non-transplantable organs for research. Through its Statline subsidiary, it has managed more than 11.3 million donor referrals. For more information, visit www.mtfbiologics.org .
About Bioventus
Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The orthobiologic products from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.BioventusGlobal.com and follow the company on Twitter @Bioventusglobal .
Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190606005422/en/
Contact:
Thomas Hill 919-474-6715 thomas.hill@bioventusglobal.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 202522.10.2025 18:00:00 CEST | Press release
Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced that it will present new data from its proprietary Targeted Protein Degradation (TPD) and Proximity Inducer Platform (A-PROX) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held at the Hynes Convention Centerin Boston, MA, from October 22–26, 2025. Aurigene’s A-PROX platform integrates library screening, direct-to-biology chemistries, proprietary ternary complex assays, modelling algorithms, and structure-based design to accelerate the discovery and optimization of both protein degraders, molecular glues and proximity inducers. Through this integrated approach, Aurigene has advanced a strong pre-clinical portfolio of next-generation degraders, includinga SMARCA2-selective degrader, which recently received Investigational New Drug (IND) approval from the United States Food and Drug Administration (FDA); a pan-KRA
Visa Live Takes Flight with Benson Boone at the Rocket Garden22.10.2025 17:30:00 CEST | Press release
From le Louvre to the Launch Pad, Visa Live returns with another unforgettable music experience that puts fans at the center of the action. Prepare for lift-off this November as Visa presents another unforgettable cultural moment with Visa Live at the Rocket Gardenfeaturing global chart-topping sensation, Benson Boone on November 29. After the global success of Visa Live at le Louvre, the next chapter of the series lands at one of the world’s most iconic locations, the Rocket Garden at Kennedy Space Center Visitor Complex in Merritt Island, Florida. Headlined by Benson Boone, with a special guest to be announced, this event will be livestreamed on TikTok, inviting fans everywhere to join a night of music under the stars in a setting typically reserved for daylight exploration. “The Visa Live experience speaks to a fundamental truth in music: the space or environment in which the music is performed actually matters to both the artist and the audience,” said Frank Cooper III, Chief Marke
Stronghold's SHx Token Lists on Kraken Exchange22.10.2025 17:30:00 CEST | Press release
Driving the Next Wave of Fintech Innovation: Infrastructure Leader Expands Access to Utility Token Stronghold today announced that its SHx token is now available for trading on Kraken, one of the world's most trusted and secure cryptocurrency exchanges. Trading begins at 8:00 AM PST, marking SHx's first listing on a U.S.-based exchange and a significant expansion in accessibility for the token that powers payments, settlements, and community governance within the Stronghold ecosystem. "Listing on Kraken brings SHx to one of crypto's most sophisticated audiences, traders, and builders who understand utility-driven tokens. This is about liquidity, interoperability, and connecting our real-world payment infrastructure to a platform that shares our commitment to security, compliance, and transparency." — Tammy Camp, CEO & Co-Founder, Stronghold SHx operates on the Stellar blockchain as Stronghold's native utility token, enabling ecosystem governance, DeFi-based financing, and value transfe
Marjan and RAK Hospitality Holding Announce Landmark Merger to Shape The Future Of Ras Al Khaimah As A Global Destination for Lifestyle and Investment22.10.2025 17:17:00 CEST | Press release
Marjan, the master developer of freehold properties in Ras Al Khaimah, and RAK Hospitality Holding, the government-owned investment and development arm in the Emirate, have announced a landmark strategic merger to create a unified entity operating under Marjan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022275206/en/ Marjan and RAK Hospitality Holding Announce Landmark Merger To Shape The Future Of Ras Al Khaimah As A Global Destination For Lifestyle And Investment (Photo: AETOSWire) This merger combines world-class hospitality expertise with visionary land development strategies to form a dynamic future-ready organization. Marjan will integrate real estate development, hospitality operations, and lifestyle experiences under one umbrella, positioning itself as one of the largest real estate developers in the UAE and the leading master developer in the Northern Emirates. Announcing the merger, His Highness Sheikh Ahmed
Venture Global Statement on CP2 Final Approval22.10.2025 16:33:00 CEST | Press release
The U.S. Department of Energy issued the final non-FTA export authorization for Venture Global’s CP2 facility in Cameron Parish, Louisiana. Venture Global CEO Mike Sabel issued the following statement: “Venture Global is grateful for the Trump Administration’s final approval of CP2, a critical project that will supply American allies with low-cost LNG for decades, support thousands of jobs and greatly benefit the U.S. balance of trade. The CP2 project construction is well underway and we look forward to continue advancing the project safely and quickly to bring new LNG to the global market at a record pace beginning in 2027.” About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (LNG) with over 100 MTPA of capacity in production, construction, or development. Venture Global began producing LNG from its first facility in 2022 and is now one of the largest LNG exporters in the United States. The company’s vertically integrated bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom